A total of 432 patients (56.3% women) aged 12 and older with psoriasis on the scalp and body were randomly assigned to two groups, one of which used roflumilast foam 0.3% once a day for eight ...

Central adiposity measures are strongly associated with psoriasis risk, with a stronger association in women, according to a ...

E et al.Poster Number 62155 Roflumilast Foam 0.3% in Patients With Scalp and Body Psoriasis: Improvements in Patient-Reported Outcomes (ARRECTOR)Gooderham, M et al.Poster Number 62151 ...

Zoryve foam, 0.3% is a once-daily topical treatment for plaque psoriasis on the body and scalp. The Food and Drug Administration (FDA) has approved Zoryve ® (roflumilast) topical foam ...

Researchers have found that central body fat, especially around the abdomen, is more strongly linked to psoriasis risk than total body fat, particularly in women. This link between central fat and ...

Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase III trial. Improvements in scalp itch were also greater for patients ...

Medscape Medical News, May 29, 2025 Alert FDA Approves Roflumilast Foam for Scalp, Body Psoriasis The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic ...

Researchers have found that central body fat, especially around the abdomen, is more strongly linked to psoriasis risk than total body fat, particularly in women. This link between central fat and ...

In the study, "Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body," published in JAMA Dermatology, researchers conducted a double-blinded, placebo-controlled, randomized clinical trial to ...

Once-daily 0.3% topical roflumilast foam significantly reduced severity in patients with psoriasis of the scalp and body over 8 weeks, with a favorable safety profile. “Use of roflumilast foam ...